KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
8.75
+0.45 (5.42%)
Jan 21, 2025, 4:00 PM EST - Market closed
KalVista Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
150
Market Cap
432.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
KALV News
- 1 day ago - KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema - Business Wire
- 14 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha
- 5 weeks ago - KalVista Appoints Jeb Ledell as Chief Operating Officer - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update - Business Wire
- 2 months ago - KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors - Business Wire
- 2 months ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire